LDL

NorthSea Therapeutics Provides Clinical Update Reflecting Progress Across NASH And Metabolic Disorders Programmes

Retrieved on: 
Thursday, January 5, 2023
Biotechnology, Vitamins, Supplements, Health, Pharmaceutical, Clinical Trials, Apolipoprotein, Fibrosis, Short bowel syndrome, CSO, NST, Organic acid, Radio Northsea International, Fatty liver disease, Parenteral nutrition, Phase II, LDL, ICONA, Apolipoprotein B, NASH, Biomarker, Patient, Liver injury, SEFA, Hypertriglyceridemia, Diabetes, Pharmaceutical industry

NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today provides an update on its clinical pipeline of structurally engineered fatty acids (‘SEFAs’), a new class of fatty acids drugs, for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic disorders.

Key Points: 
  • NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today provides an update on its clinical pipeline of structurally engineered fatty acids (‘SEFAs’), a new class of fatty acids drugs, for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic disorders.
  • NST’s lead product, icosabutate, is a once-daily, oral SEFA currently in a Phase 2b clinical trial (ICONA) for the treatment of non-alcoholic steatohepatitis, or NASH.
  • The study’s primary endpoint is resolution of NASH without worsening of fibrosis, based on changes in liver biopsy parameters compared to baseline after 52 weeks.
  • Icosabutate was also well-tolerated, with no serious safety signals to date, a key attribute for patients with NASH, who require chronic therapy.

InsideTracker Adds Apolipoprotein B (ApoB) Testing To Popular "Ultimate Plan"

Retrieved on: 
Tuesday, January 3, 2023
Degenerative disease, Longevity, InsideTrack, Apolipoprotein B, Health, Atherosclerosis, Risk, LDL, Triglyceride, Death, HDL, Scientific Reports, Genetics, Ageing, Doctor of Philosophy, Research, Biomarker, Dietary supplement, Medical imaging, Science

CAMBRIDGE, Mass., Jan. 3, 2023 /PRNewswire/ -- InsideTracker, the leading personal health analysis and data-driven wellness guide that helps people increase their healthspan and live healthier longer, announced today the company's popular Ultimate Plan will now also measure Apolipoprotein B (ApoB)—an essential indicator of heart health.

Key Points: 
  • Apolipoprotein B, commonly known as ApoB, is the main protein found in low-density lipoproteins.
  • However, emerging research indicates that ApoB is an essential indicator of heart health and heart disease risk.
  • By analyzing your body's biomarkers, InsideTracker provides an objective assessment of the current state of your well-being.
  • Integrated within an intuitive mobile app, InsideTracker reveals your personalized path to improving your health and longevity from the inside out.

Prioritize Heart Health with a Balanced Eating Plan

Retrieved on: 
Monday, December 19, 2022
Degenerative disease, Microsoft family features, Family, Risk, National Heart, Lung, and Blood Institute, DASH, Cholesterol, LDL, Friends, Eating, Lung, Salmon, Research, Social support, Medical device, Dietary supplement, Fast food, Mediterranean Sea

Small changes, like following a healthier eating plan, can help you start down a path toward improved heart health.

Key Points: 
  • Small changes, like following a healthier eating plan, can help you start down a path toward improved heart health.
  • One step you can take is following the DASH eating plan, which is a flexible and balanced way of eating that stands for Dietary Approaches to Stop Hypertension and was developed by the National Heart, Lung, and Blood Institute.
  • Being more physically active, managing stress, getting quality sleep and not smoking combined with DASH can put you on a path toward a healthy heart for life.
  • Research shows social support and personal networks make it more likely you'll stick to healthy habits like eating healthy.

Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, Security (finance), Standard of care, Allergic conjunctivitis, Observation, Analysis, Plasma, Pharmacology, Financial condition report, Patient, Toxicity, Conversation, Annual report, Assistant, HIV disease progression rates, Duane syndrome, COVID-19, Data analysis, Ethanol, Flushing, Growth, Clinical trial, University of Louisville School of Medicine, Failure, Safety, University, RASP, Inflammation, Marketing, Acetaldehyde, LDL, Result, Proprioception, Risk, Pharmaceutical industry, Vaccine, Medicine

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced demonstration of target engagement and improvement in the signs of alcohol intoxication in a sequence-randomized, double-masked, placebo-controlled crossover Phase 2 clinical trial of ADX-629, a first-in-class orally administered investigational new drug candidate.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced demonstration of target engagement and improvement in the signs of alcohol intoxication in a sequence-randomized, double-masked, placebo-controlled crossover Phase 2 clinical trial of ADX-629, a first-in-class orally administered investigational new drug candidate.
  • Post-baseline assessments occurred when target blood alcohol concentrations were reached and again over the following day.
  • Based on the results of the alcohol challenge clinical trial, Aldeyra plans to support an investigator-sponsored Phase 2 clinical trial of ADX-629 in moderate alcoholic hepatitis.
  • ADX-629, an investigational new drug, is a novel, orally administered RASP (reactive aldehyde species) modulator for the potential treatment of systemic immune-mediated diseases.

Star Olive Oils are now Certified by the American Heart Association's Heart-Check Food Certification Program

Retrieved on: 
Monday, December 12, 2022
Olive, American Heart Association, North American Olive Oil Association, Olive oil, International Olive Council, EVOO, Extra virgin, Food, Supermarket, Intake, Institute for Physico-Medical Research, Food packaging, STAR, Light, IOC, Nutrition facts label, Degenerative disease, Originality, Criticism of the Food and Drug Administration, LDL, Stroke, Risk, Dietary supplement, Vegetable oil, Oil, Jorge Luis Borges

FRESNO, Calif., Dec. 12, 2022 /PRNewswire/ -- The STAR line of Olive Oils, a Borges brand, are now certified by the American Heart Association's Heart-Check Food Certification Program. The Heart-Check mark on food packaging helps take the guesswork out when reading Nutrition Facts and label information, signaling to consumers the product meets the nutritional requirements of the American Heart Association's long-standing program and can be included as part of an overall healthy eating pattern.

Key Points: 
  • FRESNO, Calif., Dec. 12, 2022 /PRNewswire/ -- The STAR line of Olive Oils, a Borges brand, are now certified by the American Heart Association's Heart-Check Food Certification Program.
  • STAR Olive Oils also feature the North American Olive Oil Association (NAOOA) seal and validation of authentic olive oil content.
  • STAR line of Olive Oils includes Extra Virgin Olive Oil, EVOO Robust, EVOO First Harvest, EVOO Organic and Light and Original testing olive oils.
  • The North American Olive Oil Association (NAOOA) conducts the nation's largest and most complete olive oil testing and certification program from Oils.

Mirum Pharmaceuticals Provides Development Program Updates

Retrieved on: 
Tuesday, November 29, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Growth, Itch, IBAT, Cholestasis, ICP, Recycling, LDL, European Directive on Traditional Herbal Medicinal Products, PSC, Alagille syndrome, Patient, Medication, Royal commission, Primary biliary cholangitis, European Commission, CHMP, Security (finance), Primary sclerosing cholangitis, VISTAS, PBC, PFIC, Biliary atresia, Spiroplasma mirum, Cholestatic pruritus, European Committee of the Regions, Pregnancy, Institute of Liver and Biliary Sciences, Liver, Volixibat, Pharmaceutical industry, Food delivery

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the decision to discontinue the OHANA study of volixibat in intrahepatic cholestasis of pregnancy (ICP) due to enrollment feasibility.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the decision to discontinue the OHANA study of volixibat in intrahepatic cholestasis of pregnancy (ICP) due to enrollment feasibility.
  • Mirum is continuing to advance its broad pipeline of indications where LIVMARLI and volixibat have the potential for life-changing impact for patients.
  • Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases.
  • In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.

Beyond Meat® and American Cancer Society to Advance Research on Plant-Based Meat and Cancer Prevention

Retrieved on: 
Monday, November 14, 2022
American Cancer Society, Taste, TMAO, Hormone, World Health Organization, Meat, Red meat, Risk, LDL, Environmental impact of meat production, Data collection, Stanford University, The American Journal of Clinical Nutrition, Doctor of Philosophy, GoBeyond Student Travel, Cancer, Human, Natural Resources, Diet, Research, Tobacco, Genetically modified organism, ACS, Mortality, Stanford University School of Medicine, Annual report, American Journal, Climate change, Health, Colorectal cancer, BYND, Cholesterol, Degenerative disease, Dietary supplement, Agriculture, Birth control, Beyond Meat, Medicine

American Cancer Society guidelines have long recommended a diet rich in plant foods with limited intake of processed and red meat, said William L. Dahut, M.D., Chief Scientific Officer at the American Cancer Society.

Key Points: 
  • American Cancer Society guidelines have long recommended a diet rich in plant foods with limited intake of processed and red meat, said William L. Dahut, M.D., Chief Scientific Officer at the American Cancer Society.
  • We are honored to enter this agreement with the American Cancer Society, a leading authority on cancer research, said Beyond Meat CEO Ethan Brown.
  • For years, the American Cancer Society investigators conducted foundational work identifying the link of red and processed meat to cancer.
  • Beyond Meat is not involved and does not have input in the research or data collection of the American Cancer Society.

Beren Awarded Expedited Roadmap for Treatment of Homozygous Familial Hypercholesterolemia

Retrieved on: 
Thursday, November 17, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Cardiology, Atherosclerosis, SMC, MAA, NICE, TDP, Infarction, National Health Service, Patient safety, Plaque, LDL, Therapy, Quality of life, Medicine, MHRA, Marketing, NHS, Disease, HEART, Acceleration, Public health, Healthcare Improvement Scotland, Artery, Patient, United, Pharmaceutical industry

(Beren), a biotechnology company, today announced that its novel lead asset, BRN-002, was awarded an Innovation Passport under the United Kingdoms Innovative Licensing and Access Pathway (ILAP), for the reversal of atherosclerosis in patients with Homozygous Familial Hypercholesterolemia (HoFH).

Key Points: 
  • (Beren), a biotechnology company, today announced that its novel lead asset, BRN-002, was awarded an Innovation Passport under the United Kingdoms Innovative Licensing and Access Pathway (ILAP), for the reversal of atherosclerosis in patients with Homozygous Familial Hypercholesterolemia (HoFH).
  • The ILAP aims to accelerate the time to market for innovative medicines that address the needs of patients with life-threatening or seriously debilitating diseases.
  • The disease is currently managed with LDL-apheresis beginning as early as the age of seven and other LDL-lowering therapies.
  • Despite the current therapies and treatments, the average patient life expectancy is between 30 and 40 years.

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

Retrieved on: 
Thursday, November 17, 2022
Fatty liver disease, Cholesterol, Security (finance), Type 2 diabetes, TASE, Department of Medicine – University of Pamplona, Breakfast, Biotechnology, Knowledge, Legislation, Liver, HDL, Safety, Research, KPA, Chronic liver disease, NASH, Concentration ratio, LDL, Fibrosis, Liver disease, Steatosis, Hebrew language, Market, CAP, Death, Glycated hemoglobin, Patient, NAFLD, Inflammation, Non-alcoholic fatty liver disease, Liver failure, Pressure, Clinical trial, Diabetes, Incidence, MRI, Type 2, Diagnosis, Liver cancer, Cirrhosis, POD, Dietary supplement, Pharmaceutical industry, Medical imaging, Surveying, Lipid, Triglyceride, Oramed, T2D

In this patient population, the safety of a potential therapy is of paramount importance."

Key Points: 
  • In this patient population, the safety of a potential therapy is of paramount importance."
  • "We are very encouraged by the detailed data reported today demonstrating a positive safety profile and signs of efficacy for our oral insulin program to treat NASH," said Oramed's Chief Executive Officer, Nadav Kidron.
  • As previously announced, the Phase 2 trial enrolled 32 patients (with 30 patients completing) over a treatment period of 12-weeks.
  • ORA-D-N02 is a Phase 2 double-blind, randomized, placebo-controlled, multicenter trial to assess the safety and efficacy of Oramed's oral insulin candidate, ORMD-0801, to reduce liver fat content in T2D patients with NASH.

Family Heart Foundation Study Shows Significant Health Disparities in Treatment of Familial Hypercholesterolemia

Retrieved on: 
Monday, November 7, 2022
Cardiology, Health, Philanthropy, General Health, Research, Family, Foundation, Public Policy, Government, Advocacy Group Opinion, Consumer, Science, People, American Heart Association, Female, Male, Observational study, Research, Foundation, Education, Machine learning, Ezetimibe, Degenerative disease, FH, Prescription, Infarction, Mutation, Stroke, Data analysis, Income, Probability, Artery, White, Data, LDL, Risk, Gene, Policy, Diagnosis, Patient, Hope, Medical device, Dietary supplement, Medicine, Pharmaceutical industry, Facebook

The Family Heart Foundation , a leading research and advocacy organization, shared results from an analysis of its large U.S. Family Heart DatabaseTM showing significant disparities exist in the treatment of familial hypercholesterolemia (FH) among racial groups, and by income and education levels.

Key Points: 
  • The Family Heart Foundation , a leading research and advocacy organization, shared results from an analysis of its large U.S. Family Heart DatabaseTM showing significant disparities exist in the treatment of familial hypercholesterolemia (FH) among racial groups, and by income and education levels.
  • These findings highlight the significant unmet need for improving equity and providing all individuals with FH an opportunity for cardiovascular risk reduction.
  • The observational study included patients diagnosed with FH and those likely to have FH but not yet diagnosed (probable FH).
  • Probable FH patients were identified by the Family Heart Foundations validated FIND-FH machine learning model.